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Meningococcal disease (MD) remains an important infectious cause of life threatening infection in both 
industrialized and resource poor countries. Genetic factors influence both occurrence and severity of 
presentation, but the genes responsible are largely unknown. We performed a genome-wide association 
study (GWAS) examining 5,440,063 SNPs in 422 Spanish MD patients and 910 controls. We then 
performed a meta-analysis of the Spanish GWAS with GWAS data from the United Kingdom (combined 
cohorts: 897 cases and 5,613 controls; 4,898,259 SNPs). The meta-analysis identified strong evidence of 
association (P-value ≤ 5 × 10−8) in 20 variants located at the CFH gene. SNP rs193053835 showed the 
most significant protective effect (Odds Ratio (OR) = 0.62, 95% confidence interval (C.I.) = 0.52–0.73;  
P-value = 9.62 × 10−9). Five other variants had been previously reported to be associated with 
susceptibility to MD, including the missense SNP rs1065489 (OR = 0.64, 95% C.I.) = 0.55–0.76, 
P-value = 3.25 × 10−8). Theoretical predictions point to a functional effect of rs1065489, which may 
be directly responsible for protection against MD. Our study confirms the association of CFH with 
susceptibility to MD and strengthens the importance of this link in understanding pathogenesis of the 
disease.
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Meningococcal disease (MD), caused by Neisseria meningitidis, is an important cause of meningitis and septi-
caemia in children and young adults globally; it is associated with average mortality rates of 10% and long-term 
disability in survivors despite early diagnosis, antibiotic administration, and intensive care1,2. Global N. men-
ingitidis serogroup distribution is varied and dynamic, making trends in disease epidemiology unpredictable3. 
Introduction of conjugate vaccines against serogroup C and A have drastically reduced its incidence in several 
countries4. However failure of wide implementation of the available conjugated vaccines against serogroups A, B, 
C, Y, and W-135 still makes MD a major challenge worldwide5.
There is now strong evidence that host genetic factors influence occurrence of MD, and a number of genes 
controlling susceptibility and severity of MD have been identified in candidate gene association studies6,7. Our 
previous genome-wide association study (GWAS) on a UK population sample, with validation in Western and 
southern European cohorts, identified genetic variations in the regulation of complement activation, complement 
factor H (CFH) and complement factor H related 3 (CFHR3) contributing to MD susceptibility8.
In order to identify new genetic associations with susceptibility to MD we carried out a GWAS in a cohort of 
Southern European (Spanish) MD cases and controls, and then undertook meta-analysis combining our South 
European GWAS with the previously published UK GWAS.
Results and Discussion
Clinical and demographic data of Southern Europe (Spanish) and UK cohorts are summarized in Table 1.
In the Spanish MD cohort, we genotyped a total of 1,488 samples with 561,880 SNPs using the Illumina Quad 
660W array, of which 42 samples had call rates < 90% and were excluded. We detected 45 pairs of samples with 
suspected first-degree relationships. The sample with the lower call rate among each pair of relatives was removed 
to break any potential first-degree familial relationship in the cohort. In addition, a total of 69 samples were 
detected as significant ancestry outliers in the principal component analysis (PCA), and were also excluded, leav-
ing a total of 422 MD cases and 910 controls for further imputation and association analyses. We also filtered the 
genotyped SNPs, removing those with call rate < 95% (n = 1,258), those where the Hardy-Weinberg equilibrium 
(HWE) test showed significant deviation at P-value < 10−7 in controls (n = 12,754 SNPs), as well as SNPs not in 
human genome build 37 (n = 1,475). The final post QC dataset containing 546,393 SNPs was used to impute gen-
otypes based on the 1000 Genomes Project Phase 1 reference data9 for an additional 6,749,004 SNPs, with impute 
probability of 90% and filtered with information score ≥ 0.90. We filtered the post-imputed dataset with the same 
QC criteria, including a minor allele frequency (MAF) filter of ≥ 1%, to have 5,440,063 SNPs in 422 MD cases 
and 910 controls. A mild degree of genetic stratification was observed (λ GC value = 1.133) when we performed 
direct single SNP association analyses on the 5,440,063 SNPs, and hence we adjusted for the top 4 genetic axes 
of population ancestry on the association analysis, which lowered the λ GC value to 1.03, Supplementary Data 
Figures S1A and S2A.
Details on, and data analysis for the UK GWAS cohort have been previously described8. From a starting 
number of 547 initially genotyped UK MD cases, a total of 72 samples were excluded from the study because 
they either failed genotyping (n = 6), were discrepant between clinically assigned and genotyped gender (n = 4), 
had a genotyping call rate below 95% (n = 17), were duplicates (n = 2), or were identified as a population outlier 
by PCA (n = 43). This left 475 UK MD cases for genetic association analysis. We used genome-wide genotyping 
data from UK healthy controls: 2,482 members of the 1958 Birth cohort (58BC), and 2,587 healthy blood donors 
from the National Blood Service (NBS) from the WTCCC2 project (http://www.wtccc.org.uk/ccc2). Out of 5069 
controls, 4,703 passed stringent quality control filters and were included in final analysis. For this GWAS, a total 
of 516,963 SNPs, in common between the cases and controls, passed stringent quality control filters (per-SNP 
call rate of > 95%, with HWE P > 10−7, present in human genome build 37). These SNPs were used to impute 
genotypes based on the 1000 Genomes Project Phase 1 reference data9, for an additional 7,453,462 SNPs; with 
impute probability of 90% and filtered with information score ≥ 0.90. We also filter the post imputed dataset with 
the same QC criteria, including a MAF filter of ≥ 1%, to have 5,365,603 SNPs in 475 UK MD cases and 4703 UK 
population controls.
Ancestry analysis of the UK sample collection showed that the MD cases and controls were well matched 
(Supplementary Data Figures S1B and S2B). In this light, the 1-degree of freedom (d.f.) score test for association 
performed in the UK dataset was not further adjusted for axes of genetic ancestry.
Given that this study has a total of 897 cases and 5614 controls, it has 0.969 power to reject the null hypothe-
sis, considering that the risk allele frequency is at least 10%, the effect size (OR) is 0.6, and an uncorrected alpha 
threshold P-value = 0.05.
We observed minimal genome-wide inflation of the association test statistics when the UK and Spanish MD 
collections were analyzed separately (Supplementary Data Figure S1A,B), and thus formal meta-analysis for both 
sample collections was conducted under the fixed effects model using inverse-variance pooling as well as the ran-
dom effects model, that were compared to show similar significance in P-values.Single SNP association tests from 
the meta-analysis between the Spanish and UK collections revealed an excess of significant P-values at the tail end of 
the distribution (Supplementary Data Figure S1C). Observed against a background of minimal genomic inflation, 
this suggests that at least some of these significant P-values (< 10−5) could represent true associations with MD.
A total of 20 SNPs surpassed genome-wide significance (P-value ≤ 5 × 10−8) in the meta-analysis study of 
the two European cohorts that jointly include 897 MD cases and 5,613 controls (Fig. 1; and Supplementary Data 
Figure S3A,B for Manhattan plots on individual cohorts). A heterogeneity test showed non-significant values, 
indicating that the association was in the same direction in the two cohorts. The 20 SNPs fall in the CFH gene 
(located on chromosome 1q32–q32.1) or very close to this gene (rs72482675).
We found the strongest evidence of association with protection to MD susceptibility at SNP rs193053835 
(P-value = 9.62 × 10−9 per-allele OR = 0.62, 95% C.I. = 0.52–0.73) (Fig.  2) followed by rs72482675 
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(P-value = 1.25 × 10−8 per-allele OR = 0.63, 95% C.I. = 0.54–0.74) and rs105980 (P-value = 1.28 × 10−8 per-allele 
OR = 0.62, C.I. = 0.52–0.73); Table 2 and Supplementary Dataset S1. Other SNPs with P-values < 1 × 10−5 are 
shown in Supplementary Dataset S2. For the purpose of discovery novel candidate loci, we re-scanned the 
genome after conditioning on the top SNPs (rs1065489 and rs193053835; see Supplementary Data Figure S4), but 
we did not find other SNPs significantly associated (P-value ≤ 5 × 10−8) with MD.
We performed a stepwise conditional analysis to assess for the presence of independent signals among the 20 
candidate SNPs. After conditioning for the top SNPs, the significant P-values observed in other SNPs disappeared 
(Supplementary Dataset S3). In addition, many of the SNPs were found to have collinearity, indicating that the 20 
SNPs are strongly correlated with each other.
Five out of the 20 CFH associated variants were also reported to be associated with MD in Davila et al.8, 
namely, rs742855, rs1065489, rs11582939, rs11799595, and rs10489456. In addition, the SNP rs1065489 was addi-
tionally replicated in a Central European cohort10. We did not find an association with rs3753394; a SNP located 
in the promoter region that was previously reported to be associated with MD susceptibility by Haralambous 
Characteristics
Spanish GWAS UK GWAS
na nb na nb
Number of male cases (%) 419 255 (60.8) 442 237 (53.6)
Cases of meningococcal 
meningitis (%) 397 56 (14.1) 439 59 (13.44)
Cases of meningococcal 
septicaemia (%) 397 185 (46.6) 439 280 (63.78)
Cases of meningococcal 
meningitis and septicaemia (%) 397 156 (39.3) 439 100 (22.78)
Median age at admission (IQRb) 419 2.3 (0.9–5.1) 442 3.32 (1.36–8.24)
Median GMSPS (IQR) 324 0 (0–2) 394 9 (6–12)
Inotropes (%) 381 183 (48.03) 441 268 (60.77)
Mechanical ventilation (%)c 381 183 (48.03) 442 321 (72.62)
Skin graft (%) 381 8 (2.09) 442 16 (3.62)
Amputation (%) 381 9 (2.36) 442 4 (0.90)
Death (%) 419 17 (4.05) 442 18 (4.07)
Controls (European ancestry) 992 992 4703 4703
Table 1.  Demographic and clinical data of the cohorts successfully genotyped in the GWAS. na: total number 
of informative cases/controls; nb: number of cases/controls carrying the phenotype/condition indicated in rows. 
Note that there were clinical data for 442 out of the 475 UK MD cases used in the present study. IQR: interquartile 
range. n: total number of informative cases. GMSPS: Glasgow meningococcal prognostic score. In the Spanish 
cohort, mechanical ventilation refers to any kind of respiratory support, including noninvasive ventilation.
Figure 1. Genome-wide association plot for the Meningococcal meta-analysis between the Spanish and 
UK MD collections. The Y-axis denotes the strength of the association (−log10 P-value) for each SNP marker. 
The X-axis denotes individual chromosomes. The horizontal lines denote significant (P-value = 5 × 10−8) and 
suggestive (P-value = 10−5) evidence of association with disease. The red dot is the top SNP (rs193053835) with 
the minimal P-value, and the green dot is the functional candidate SNP (rs1065489).
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et al.11. Consistently, all the studies point to a protective effect of these variants, with OR values ranging (in our 
study) from 0.62 to 0.72.
Although the SNP rs12085435, recently associated by Bradley et al.12 with invasive MD, was not genotyped in 
the present study, we did not find other SNPs associated within the C8B region. In addition, other SNPs recently 
associated with Age-related Macular Degeneration (AMD) risk located within the CFH region13 did not appeared 
as associated in our meta-analysis. Moreover, we did not find genetic variation associated within CFHR3, as pre-
viously reported8.
A total of 18 out of the 20 candidate SNPs located within the CFH gene, fall in noncoding regions. The 
exceptions are rs3753396 (P-value = 2.49 × 10−8 per-allele OR = 0.64, 95% C.I. = 0.54–0.75), that represents a 
synonymous change (exon 13; Gln672Gln), and rs1065489 (P-value = 3.25 × 10−8 per-allele OR = 0.64, 95% 
C.I. = 0.55–0.76) that represents a missense variant (exon 18; Glu936Asp).
The G allele at rs3753396 reaches the highest frequency in East Asia (50%), but it appears at high frequen-
cies also in Europe and America (~18%); in Africa, however, the G variant reaches only 3.7% of the population 
(Supplementary Data Table S1). This SNP was also reported to be associated with AMD in Ref. 14.
Similarly, the minor allele T at the rs1065489 locus has a high frequency in East Asia (49.7%), while it reaches 
moderate frequencies in America (19.1%) and Europe (18.3%), and has a low frequency in Africa (3.7%). Of the 
20 candidate SNPs in CFH, the rs1065489, located in exon 19, is the only one that represents a nonsynonymous 
substitution; and it is therefore more likely to be potentially functional. The data indicate that carriers of allele 
T have a protective effect against MD, with an OR = 0.64 in the merged cohorts (Table 2 and Supplementary 
Dataset S1). As already noticed in Davila et al.8, the incidence of MD inversely parallels the MAF of this SNP. 
Thus, sub-Saharan African populations have the highest rates of disease but the lowest frequency of this polymor-
phism (Supplementary Data Figure S5 and Table S1). Supplementary Data Table S2 shows different functional 
predictions for this variant; while a number of the predictions indicate that this variant is functionally tolerated, 
Polyphen2 using the database HDIV (recommended when evaluating loci potentially involved in complex phe-
notypes) indicates that rs1065489 is possibly damaging. Most interesting, the DANN score of this SNP receives 
a value of 0.985 (ranging from 0 to 1). It has been reported that this score has the best sensitivity and specificity 
when compared to comparable scores (e.g. CADD and FATHMM). Moreover, it is worth mentioning that this 
variant is highly phylogenetically conserved in other mammals (Supplementary Data Figure S6). In addition, 
Bradley et al.12 recently described an association of this SNP with genetic susceptibility to MD. It is important 
to note that all the SNPs in the CFH region are in high linkage disequilibrium (Fig. 2 and Supplementary Data 
Figure S7), and therefore, there could be other causal SNPs (in high LD with rs1065489) conferring protection 
against MD not captured in the present GWAs.
The present study adds further support to the association in CFH to the susceptibility of MD previously 
reported by Davila et al.8. Different polymorphisms at the CFH gene were also found to be associated in a number 
of diseases, including Atypical Hemolytic Uremic Syndrome15, or AMD16. The CFH gene encodes for the protein 
Figure 2. SNPs in the CFHR genes region were plotted according to its location in the genome (X-axis) 
against the combined meta-analysis −log10 P-value in the Y-axis. The candidate SNP; rs1065489 is denoted 
as the purple circle, whereas red circles represent SNPs in LD (r2 ≥ 0.8) with rs1065489. Recombination rates 
and LD values were plotted based on the 1000 Genomes European 2012 reference, in genome build hg19. See 
also Supplementary Data Figures S8 that covers the CFHR3 and CFHR1 regions using a call rate filter > 80%.
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complement factor H, which plays an essential role regulating part of the complement system during an immune 
response. The complement system involves a cascade of proteins that work together in order to opsonize or kill 
invading pathogens. According to Schneider et al.17 N. meningitidis exploits the natural regulators (such as FH) to 
scape from the complement system and therefore from host immune control. The involvement of CFH and CFHR 
with MD appears to be through their role in inhibition of complement activation. Complement mediated killing 
is a fundamental mechanism of immunity to meningococcal invasion. Meningococci express a surface factor H 
binding protein (fHbp), which binds the host plasma protein FH and possibly FH related proteins to the bacterial 
surface with high affinity. The bacteria thus appears to use a “Trojan horse” strategy to evade complement medi-
ated killing, using the host CFH to inhibit complement activation on the bacterial surface.
The main limitation of the present study is that the study design lacks external replication stage. Further stud-
ies would therefore be needed in order to confirm the present findings. In addition, SNP rs3753396 was found to 
be protective for MD but it has been reported to be a risk factor in AMD. This interesting finding deserves also 
further investigation.
Summarizing, the fact that different population-based genome-wide studies show consistent statistical associ-
ation of the same SNPs strengthens the evidence in favor of an association of the CFH gene in MD susceptibility. 
All of the significant SNPs were identified to reside within a single haplotype, indicating that the SNPs are in LD 
and correlated with each other. Further evidence from the stepwise conditional analysis demonstrated that the 
significant P-values seen in each SNPs are not independent after conditioning for the top SNPs. The risk alleles 
of the 20 genome wide significant SNPs have odds ratio that are similar within the range of 0.62–0.72, which are 
protective towards MD. We found that the non-synonymous variant rs1065489 may be directly responsible for 
a protective effect in MD. However, further studies are needed in order to better understand the molecular and 
functional mechanisms that relate CFH variants and MD and to identify causal variants within the CFH region. 
Our findings support complement factor H as an important target for future development of therapeutic and 
preventive strategies against MD.
Material and Methods
Study participants. Diagnosis of MD was made in patients presenting with a characteristic purpuric or pete-
chial rash, and clinical evidence of meningitis and/or septicaemia6,18,19. Diagnosis was confirmed microbiologically 
SNP Position (BP) Gene location A1 Fixed-P Fixed-OR 95% CI Random-P Random-OR 95% CI Q I2 Spanish IS UK IS
rs193053835 196715667 Intron T 9.62 × 10−09 0.62 0.52–0.73 9.62 × 10−09 0.62 0.52–0.73 0.78 0 0.962 0.965
rs72482675 196716924 500 bp Downstream G 1.25 × 10
−08 0.63 0.54–0.74 1.25 × 10−08 0.63 0.54–0.74 0.82 0 0.983 0.989
rs105980 196715666 Intron A 1.28 × 10−08 0.62 0.52–0.73 1.28 × 10−08 0.62 0.52–0.73 0.83 0 0.962 0.965
rs6695321 196675861 Intron G 2.33 × 10−08 0.72 0.64–0.81 3.53 × 10−07 0.72 0.63–0.82 0.27 16.61 0.997 0.998
rs12406047 196677898 Intron T 2.38 × 10−08 0.64 0.54–0.75 2.38 × 10−08 0.64 0.54–0.75 0.77 0 0.987 0.989
rs11799595* 196700322 Intron C 2.38 × 10−08 0.64 0.55–0.75 2.38 × 10−08 0.64 0.55–0.75 0.62 0 0.992 0.995
rs3753396 196695742 Synonymous G 2.49 × 10−08 0.64 0.54–0.75 2.49 × 10−08 0.64 0.54–0.75 0.7 0 0.992 0.995
rs1048663 196674982 Intron A 2.52 × 10−08 0.64 0.54–0.75 2.52 × 10−08 0.64 0.54–0.75 0.69 0 0.986 0.989
rs74213209 196679010 Intron G 2.55 × 10−08 0.64 0.54–0.75 2.55 × 10−08 0.64 0.54–0.75 0.69 0 0.986 0.989
rs10922107 196698651 Intron T 2.61 × 10−08 0.64 0.55–0.75 2.61 × 10−08 0.64 0.55–0.75 0.62 0 0.992 0.995
rs12402808 196691625 Intron A 2.71 × 10−08 0.64 0.55–0.75 2.71 × 10−08 0.64 0.55–0.75 0.62 0 0.992 0.995
rs11801630 196692148 Intron T 2.71 × 10−08 0.64 0.55–0.75 2.71 × 10−08 0.64 0.55–0.75 0.62 0 0.992 0.995
rs742855* 196705520 Intron C 3.15 × 10−08 0.64 0.55–0.76 3.15 × 10−08 0.64 0.55–0.76 0.66 0 0.999 0.997
rs1065489* 196709774 Missense T 3.25 × 10−08 0.64 0.55–0.76 3.25 × 10−08 0.64 0.55–0.76 0.84 0 — —
rs11799380 196708455 Intron G 3.77 × 10−08 0.65 0.55–0.76 3.77 × 10−08 0.65 0.55–0.76 0.8 0 0.999 0.999
rs2336221 196708891 Intron T 3.77 × 10−08 0.65 0.55–0.76 3.77 × 10−08 0.65 0.55–0.76 0.8 0 1 0.999
rs11582939* 196710157 Intron A 3.87 × 10−08 0.65 0.55–0.76 3.87 × 10−08 0.65 0.55–0.76 0.8 0 — —
rs1831280 196683274 Intron G 4.22 × 10−08 0.64 0.55–0.76 4.22 × 10−08 0.64 0.55–0.76 0.8 0 0.986 0.989
rs11584505 196679927 Intron C 4.35 × 10−08 0.65 0.55–0.76 4.35 × 10−08 0.65 0.55–0.76 0.79 0 0.986 0.989
rs10489456* 196687515 Intron A 4.56 × 10−08 0.65 0.55–0.76 4.56 × 10−08 0.65 0.55–0.76 0.73 0 0.992 0.995
Table 2.  SNPs located at the CFH gene (chromosome 1) statistically associated with MD in the merged 
ESIGEM-UK cohort. An asterisk indicates those SNPs that were reported previously as associated with MD 
susceptibility. Position in base pairs (bp) are given according to GRCh37/hg19. A1: risk allele; Fixed-P: fixed-
effects meta-analysis P-value; Fixed.OR: fixed-effects meta-analysis odds ratio estimate with reference to 
the risk allele; in brackets is the 95% confidence interval; Random-P: random-effects meta-analysis P-value; 
Random-OR: Random-effects meta-analysis odds ratio estimate with reference to the risk allele; in brackets 
is the 95% confidence interval. Q: P-value for Cochrane’s Q statistic; I2: I-squared index between sample 
collections, with values ranging from 0 (no heterogeneity) to 100 (very high heterogeneity). I2 value < 50 
indicates heterogeneity is not significant. Spanish IS: information on info score for SNPs that were imputed 
in the Spanish GWAS cohort. UK IS: information score for SNPs that were imputed in the UK GWAS cohort. 
rs1065489 and rs11582939 were directly genotyped.
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by culture of N. meningitidis from blood or CSF, or by PCR for meningococcal DNA in blood. Individuals in 
whom microbiological studies were negative, but presented with a characteristic clinical picture of shock, pur-
puric rash or meningitis, were also included once other pathogenic bacteria or virus infection were ruled out20. 
Table 1 summarizes the clinical and demographic data of the Spanish and UK cohorts. All patients included in the 
present study were of European descent. The initial Southern European cohort consisted of 496 MD cases present-
ing between 2006–2009 to hospitals included in the Spanish MD research network ESIGEM (www.esigem.org) 
comprising 43 pediatric intensive care units coordinated from the Hospital Clínico Universitario of Santiago de 
Compostela (Galicia, Spain); for more information on these samples see Ref. 8. The initial UK cohort consisted 
of 547 patients enrolled at UK hospitals between 1995 and 20078. Clinical details on the UK cohort have been 
previously reported21–23.
Each MD case cohort was accompanied by geographically matched healthy controls. Thus, 992 unrelated 
healthy Spanish ethnically matched controls were recruited at the same time as the MD cases; a subset of this sam-
ple has been previously described24. UK controls for GWAS have already been described8; in brief, the genotypic 
data consisted of 4,703 individuals from the Wellcome Trust Case-Control Consortium 2 (WTCCC2)8.
The research was performed in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical 
Practice, the convention of the Council of Europe on Human Rights and Biomedicine and with the ethical prin-
ciples laid down in the Declaration of Helsinki. The project was submitted and approved by the ethics committee 
of each participating site, namely, Ethics Committee of Galicia (Spain) and NRES Committee London (United 
Kingdon). Parents information sheets and informed consent forms were also submitted and approved. Informed 
consent (Informed assent when applicable) was obtained from parents/legal guardians of subjects (subjects when 
applicable) included in the study prior to any study procedure. The study was performed in compliance with 
National and European normative that is applicable for human research and data protection. Confidentiality of 
the identity of the participants was also safeguarded.
Genotyping and data quality control. DNA was extracted from blood samples using established lab-
oratory techniques. The MD cases were genotyped using the Illumina Human 660W Quad BeadChips for the 
Spanish collection, and the Illumina Human 610 K Quad BeadChips for the UK collection following manufac-
turer instructions.
The Spanish controls were genotyped using the Illumina 660W Quad BeadChip. The UK controls (drawn from 
the Wellcome Trust Case-Control Consortium 2; WTCCC2) were genotyped using the Illumina HumanHap 
1.2M chip. Access to raw data for this control dataset was granted by The Wellcome Trust Consortium Data 
Access Committee for our study.
After pre-phasing the Spanish and UK GWAS datasets using SHAPEIT25, IMPUTE2 was used to perform 
imputation for additional SNPs genotype using the 1000 Genomes phase 1 (Feb 2012 release) cosmopolitan pop-
ulations, as reference; Ref. 9. We used cosmopolitan multi-ethnic groups as reference for imputation because 
there is evidence performed on cosmopolitan panels versus population specific panels demonstrating that in 
general, the additional unrelated samples help to improve the imputation accuracy, in particular for the low fre-
quency SNPs. Moreover, this procedure does not seem to penalize or reduce the accuracy, even when additional 
redundant samples are added as reference in the imputation26.
A selection of stringent quality control (QC) filters were applied to the genome-wide genotyping data to 
remove poorly performing SNPs and samples, using tools implemented in PLINK version 1.07 (Ref. 27). SNPs 
that had > 5% of missing genotypes, gross departure from HWE (test for HWE showing significant deviation at 
P -value < 10−7 in controls) or were of MAF below 1% were excluded from downstream analysis. For QC, samples 
with an overall genotyping call rate of < 95% were excluded from analysis. Most of the SNPs located in the CFHR1 
and CFHR3 genes were filtered due to a poor call rate at this region. We therefore used a more relaxed filter (call 
rate > 80%) in order to retain SNPs at these genes. However, the combined meta-analysis did not revealed better 
SNP candidates (Supplementary Data Figure S8A,B,C).
Samples were subjected to biological kinship verification by using the principle of variability in allele sharing 
according to the degree of relationship. Identity-by-state (IBS) information was derived using PLINK. Pairs of 
samples predicted to be first-degree relatives based on IBS sharing were identified, and the sample with the lower 
call rate of each pair was excluded from further analysis.
We combined the Spanish or UK samples with the Africans (YRI), East Asians (CHB, CHS, JPT), and samples 
with European descent (CEU, GBR, FIN, ISB, TSI) of the 1000 genomes project28,29, and used their LD-pruned 
SNPs to perform PCA as implemented in EIGENSTRAT30 and extracted the values of PC1 and PC2 to plot 
Supplementary Data Figure S2A,B. We also performed independent PCA on the Spanish GWAS dataset that 
consisted of 1332 post-QC samples, and extracted the top 4 genetic axes (PC1–PC4) of population ancestry to 
include as covariates in the SNP association analysis.
Statistical analysis. A meta-analysis was carried out on the GWAS data from the Spanish and the UK 
cohort. Statistical analyses for association were undertaken using an additive model logistic regression as imple-
mented in PLINK v1.07; Ref. 27. Principal component (PC) analysis as implemented in EIGENSTRAT30 was 
undertaken to account for spurious genetic associations resulting from ancestral differences of individual SNPs. 
PC plots were performed using the R statistical program package (www.r-project.org/).
For the independent GWAS data from Spain and UK, analysis of association with MD was undertaken using a 
1 d.f. logistic regression test, which allows further adjustment of incorporating additional principal components 
as covariates of population stratification. The combined meta-analysis on the results of both Spanish and UK col-
lections was performed using both the inverse-variance fixed effects method as well as the random effects model.
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LocusZoom31 was used to plot the CFHRs genes regional association plot using the combined fixed effect 
meta-analysis P value of SNPs located in this region. LD in the plot was estimated based on the 1000 genomes 
EUR population and using the hg19 genome build coordinates.
R2 correlation values and the D′ CI method of Gabriel et al.32 as implemented in Haploview33 were used to 
plot the pairwise LD map between the 20 genome wide significant SNPs within the Spanish GWAS samples or 
the UK samples.
Functional annotation of gene variants was carried out using ANNOVAR34. ANNOVAR obtains from 
high-throughput sequencing data, different variant functional predictions, such as: (a) SIFT (Sorting Intolerant 
From Tolerant)35 that predicts whether an amino acid substitution is likely to affect protein function based on 
sequence homology and the physico-chemical similarity between the alternate amino acids, (b) PolyPhen236: 
prediction of functional effects of human nsSNPs, (c) LRT (Likelihood Ratio Test)37 identifies a subset of deleteri-
ous mutations that disrupt highly conserved amino acids within protein-coding sequences, (d) MutationTaster38 
evaluates the disease-causing potential of DNA sequence alterations, (e) MutationAssesor: predicts the func-
tional impact of amino-acid substitutions in proteins, and (f) FATHMM or Functional Analysis Through Hidden 
Markov Models39. CADD (Combined Annotation Dependent Depletion)40 was also used for scoring the delete-
riousness of single nucleotide variants. The algorithm that runs in the DANN score uses the exact same training 
and annotation data as CADD, but using a different machine learning approach41,42.
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